Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin + Chemo + Immunotherapy in Advanced/Metastatic EGFR-Mutated Biliary Tract Cancer
NCT07598318Phase 3Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 3 trial of becotatug vedotin in cholangiocarcinoma (CCA), sponsored by Sir Run-Run Shaw Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT07598318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07598318.